Tvardi Therapeutics lands $9 mln Series A
Houston, Texas-based Tvardi Therapeutics, a biopharmaceutical company focused on developing STAT3 inhibitors, has closed $9 million in Series A financing. The investors were not named.
21 September 2018•1 min read
